MedTrace Logo

Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer

NCT06457789 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2025-04-02

No results posted yet for this study

Summary

The iRelate is a PET imaging trial to compare two upcoming and promising T cell PET tracers. Following chemo-immuno therapy, as part of standard care, NSCLC patients will be recruited to receive two PET scans, shortly before their surgery. Both PET scans will be compared to each other, as well as compared to the pathological analysis of the resected tumor.

This study will provide detailed information on the unique as well as additive capacities of imaging biomarkers derived from the immune cell targeting PET tracers.

Conditions

Interventions

DRUG

[18F]F-AraG PET imaging

Patients will receive a static whole-body PET scan following a \[18F\]F-AraG injection.

DRUG

[89Zr]Zr-Df-Crefmirlimab PET imaging

Patients will receive a static whole-body PET scan following a \[89Zr\]Zr-Df-Crefmirlimab injection.

Sponsors & Collaborators

Principal Investigators

  • Idris Bahce, MD, PhD · Amsterdam UMC

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-01
Primary Completion
2027-08-31
Completion
2028-07-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06457789 on ClinicalTrials.gov